Loomis, Sayles & Company
BIVV

Loomis, Sayles & Company’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Loomis, Sayles & Company’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-251,914
Closed -$13.6M – 959
2017
Q4 		$13.6M Buy
251,914
+89,920
+56% +$4.92M 0.03% 366
2017
Q3 		$9.24M Sell
161,994
-12,778
-7% -$748K 0.02% 445
2017
Q2 		$10.5M Buy
+174,772
New +$9.95M 0.02% 410

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Loomis, Sayles & Company's BIVV Position: Q1 2018 in Review

Loomis, Sayles & Company sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 251,914 shares — an estimated $13.6M sold.

Loomis, Sayles & Company first reported a position in BIVV in Q2 2017 and held it in 3 quarters. The position peaked at $13.6M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Loomis, Sayles & Company reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 251,914 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $13.6M.
  • Loomis, Sayles & Company first reported a position in Bioverativ Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • Loomis, Sayles & Company's Bioverativ Inc. Common Stock position peaked at $13.6M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Loomis, Sayles & Company's 13F filing for Q1 2018, filed 11 May 2018.